Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis

Inclusion Criteria: * A confirmed diagnosis of relapse-remitting or secondary progressive multiple sclerosis, according to most recent McDonald's criteria (Thompson et al., 2018). This diagnosis must not be more recent than 3 months * Must have fatigue as a complaint, and an FSMC score corresponding to at least moderate fatigue (\>53) * Stable MS medication for at least 3 months Exclusion Criteria: * Pregnancy, any subject with the potential to become pregnant must ensure against this (e.g. by taking oral contraceptives, or other high efficacy method) * MS Relapse or steroid treatment within 3 months prior to inclusion * Current treatment targeted towards fatigue, or previous if discontinued within 3 months prior to inclusion * History of neurologic disease or other significant medical conditions, aside from MS * EDSS \> 6.5 * Major psychiatric disorder, including current clinical depression. * Intake of medication that primarily acts on CNS or neurotransmission, except SSRI or SNRI * Pacemaker or other implanted electronic devices * Any intracranial metal * Any metallic implant incompatible with MR scanning * Claustrophobia * Either patient or their close relatives suffering from epilepsy * Current Drug or alcohol abuse